F1 cont

being effective to stimulate or enhance antibody production in a subject, and a pharmaceutically acceptable carrier, wherein the Keyhole Limpet Hemocyanin derivative comprises Keyhole Limpet Hemocyanin linked to an immunological adjuvant.--

F2

--62. (Amended) The composition of claim 57, wherein the immunological adjuvant is a monophospholipid, a non-ionic block copolymer or a cytokine [ganglioside is conjugated to Keyhole Limpet Hemocyanin].--

--63. (Amended) The composition of claim 57, wherein the adjuvant is a [carbohydrate] saponin derivable from the bark of a Quillaja saponaria Molina tree.--

--64. (Amended) The composition of claim 63, wherein the [carbohydrate] saponin is QS-21.--

F3

--71. (Amended) A method of stimulating or enhancing antibody production in a subject which comprises administering to the subject an effective amount of a composition comprising a ganglioside conjugated through [the] a ceramide-derived carbon [portion] of the ganglioside to a Keyhole Limpet Hemocyanin or a derivative thereof and an adjuvant, the amounts of such conjugated ganglioside and such adjuvant being effective to stimulate or enhance antibody production in a subject, and a pharmaceutically acceptable carrier, wherein the Keyhole Limpet Hemocyanin derivative comprises Keyhole Limpet Hemocyanin linked to an immunological adjuvant, so as to thereby stimulate or enhance antibody production in the subject.--

--72. (Amended) A method of preventing or treating a cancer in

a subject which comprises administering to the subject an effective cancer preventing or treating amount of [the] a composition a ganglioside conjugated through a ceramide-derived carbon of the ganglioside to Keyhole Limpet Hemocyanin or a derivative thereof and an adjuvant, the amounts of such conjugated ganglioside and such adjuvant being effective to stimulate or enhance antibody production in a subject, and a pharmaceutically acceptable carrier, wherein the Keyhole Limpet Hemocyanin derivative comprises Keyhole Limpet Hemocyanin linked to an immunological adjuvant, so as to thereby prevent or treat a cancer in a subject [of claim 57].--

F3 Cont

--78. (New) The method of claim 71, wherein the cancer is of epithelial origin.--

--79. (New) The method of claim 71, wherein the cancer is of neuroectodermal origin.--

--80. (New) The method of claim 79, wherein the cancer of neuroectodermal origin is a melanoma.--

F4

--81. (New) The method of claim 71, wherein the administering is effected at two or more sites.--

--82. (New) The method of claim 81, wherein the administering is effected at three sites.--

--83. (New) The method of claim 71, wherein the immunological adjuvant is a monophospholipid A, a non-ionic block copolymer or a cytokine.--

--84. (New) The method of claim 71, wherein the wherein the

adjuvant is a saponin derivable from the bark of a Quillaja saponaria Molina tree.--

--85. (New) The method of claim 84, wherein the saponin is QS-21.--

--86. (New) The method of claim 72, wherein the immunological adjuvant is a monophospholipid A, a non-ionic block copolymer or a cytokine.--

--87. (New) The method of claim 72, wherein the adjuvant is a saponin derivable from the bark of a Quillaja saponaria Molina tree.--

F4 CONT

--88. (New) The method of claim 87, wherein the saponin is QS-21.--

--89. (New) A method of preventing relapse of a cancer in a subject which comprises administering to the subject an effective cancer relapse preventing amount of a composition comprising a ganglioside conjugated through a ceramide-derived carbon of the ganglioside to a Keyhole Limpet Hemocyanin or a derivative thereof and an adjuvant, the amounts of such conjugated ganglioside and such adjuvant being effective to stimulate or enhance antibody production in a subject, and a pharmaceutically acceptable carrier, wherein the Keyhole Limpet Hemocyanin derivative comprises Keyhole Limpet Hemocyanin linked to an immunological adjuvant so as to thereby prevent relapse of a cancer in the subject.--

--90. (New) The method of claim 89, wherein the cancer is of epithelial origin.--

--91. (New) The method of claim 89, wherein the cancer is of neuroectodermal origin.--

--92. (New) The method of claim 91, wherein the cancer of neuroectodermal origin is a melanoma.--

--93. (New) The method of claim 89, wherein the administering is effected at two or more sites.--

--94. (New) The method of claim 93, wherein the administering is effected as three sites.--

F 4 cont

--95. (New) The method of claim 89, wherein the immunological adjuvant is a monophospholipid A, a non-ionic block copolymer or a cytokine.--

--96. (New) The method of claim 89, wherein the adjuvant is a saponin derivable from the bark of a Quillaja saponaria Molina tree.--

--97. (New) The method of claim 96, wherein the saponin is QS-21.--

--98. (New) The composition of claim 57, wherein the conjugation of the ganglioside is through a carbon derived from a cleavage of a double bond in the ceramide portion of the ganglioside.--

--99. (New) The composition of claim 57, wherein the conjugation of the ganglioside is through a carbon derived from a ceramide double bond to the Keyhole Limpet Hemocyanin or a derivative thereof.--